Literature DB >> 3886224

The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders.

S N Breit, D Wakefield, J P Robinson, E Luckhurst, P Clark, R Penny.   

Abstract

The association between alpha 1-antitrypsin (alpha 1-AT) deficiency and a number of immune mediated diseases including rheumatoid arthritis, anterior uveitis, systemic lupus erythematosus, and asthma suggests that alpha 1-AT may be important not only as an anti-inflammatory protein but also as an immune regulator. That the relationship between decreased amounts of this inhibitor and these diseases is causal is suggested by both some of its physical properties and evidence indicating it is able to modulate immune function. alpha 1-Antitrypsin has a high plasma concentration, very broad range of inhibitory activity and is an acute phase reactant. Among other things, it is able to modulate lymphocyte proliferation and cytotoxicity, and monocyte and neutrophil function. Additionally, some of these changes are demonstrable in vivo in patients with severe alpha 1-antitrypsin deficiency. This paper reviews the important physicochemical characteristics of this protein, the association of its presence in decreased amounts with immune disorders, and finally the important mechanism that may underlie this disease association.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886224     DOI: 10.1016/0090-1229(85)90097-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  32 in total

1.  Bilateral central retinal artery occlusion in Wegener's granulomatosis and alpha(1) antitrypsin deficiency.

Authors:  S C Wong; R L Boyce; T C Dowd; J N Fordham
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Saving islets from allograft rejection.

Authors:  Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

3.  Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes.

Authors:  Gordon C Weir; Maria Koulamnda
Journal:  Curr Diab Rep       Date:  2009-04       Impact factor: 4.810

4.  Primary and immortalised human pancreatic islet endothelial cells: phenotypic and immunological characterisation.

Authors:  E Favaro; A Bottelli; B Lozanoska-Ochser; E Ferioli; G C Huang; N Klein; A Chiaravalli; P Cavallo Perin; G Camussi; M Peakman; P G Conaldi; M M Zanone
Journal:  Diabetologia       Date:  2005-11-15       Impact factor: 10.122

Review 5.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

6.  α-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction.

Authors:  Jingjing Wang; Zhen Sun; Wenyu Gou; David B Adams; Wanxing Cui; Katherine A Morgan; Charlie Strange; Hongjun Wang
Journal:  Diabetes       Date:  2017-01-09       Impact factor: 9.461

7.  Multiple tissues express alpha 1-antitrypsin in transgenic mice and man.

Authors:  J A Carlson; B B Rogers; R N Sifers; H K Hawkins; M J Finegold; S L Woo
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

8.  Role of a SER immune suppressor in immune surveillance.

Authors:  S K Oh; S Ross; J Walker; S Zeisel
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

9.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

10.  Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Authors:  Maria Koulmanda; Manoj Bhasin; Lauren Hoffman; Zhigang Fan; Andi Qipo; Hang Shi; Susan Bonner-Weir; Prabhakar Putheti; Nicolas Degauque; Towia A Libermann; Hugh Auchincloss; Jeffrey S Flier; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.